We are live on
!
Find out more
SA
Sicart Associates Portfolio holdings
AUM
$389M
1-Year Est. Return
42.46%
This Fund
S&P 500
This Quarter
Est. Return
+4.62%
1 Year Est. Return
+42.46%
3 Year Est. Return
+89.06%
5 Year Est. Return
+118.65%
10 Year Est. Return
–
AUM
$420M
AUM Growth
+$41.9M
(+11%)
Cap. Flow
+$32.2M
Cap. Flow
% of AUM
7.66%
Top 10 Holdings %
Top 10 Hldgs %
44.29%
Holding
115
New
10
Increased
24
Reduced
25
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Campbell Soup
CPB
|
+$7.41M |
| 2 |
Guardant Health
GH
|
+$5.45M |
| 3 |
Pfizer
PFE
|
+$4.57M |
| 4 |
Merck
MRK
|
+$4.31M |
| 5 |
Coca-Cola
KO
|
+$4.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
|
+$2.43M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$336K |
| 3 |
Cars.com
CARS
|
+$299K |
| 4 |
Albemarle
ALB
|
+$298K |
| 5 |
Wells Fargo
WFC
|
+$261K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.83% |
| 2 | Consumer Staples | 14.42% |
| 3 | Materials | 10.35% |
| 4 | Communication Services | 10.06% |
| 5 | Technology | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
SPDR Gold Trust
GLD
$131B
| $38.9M | 9.25% |
234,655
+4,150
| +2% | +$705K |
|
2
FedEx
FDX
$72.7B
| $20.7M | 4.93% |
69,359
-825
| -1% | -$245K |
|
|
WBA
3
DELISTED
Walgreens Boots Alliance
WBA
| $19.4M | 4.61% |
368,199
+4,825
| +1% | +$260K |
|
4
Kraft Heinz
KHC
$30.7B
| $18.4M | 4.38% |
451,450
+76,460
| +20% | +$3.22M |
|
5
Intel
INTC
$455B
| $16.2M | 3.85% |
288,324
+22,875
| +9% | +$1.34M |
|
6
Nutrien
NTR
$33.2B
| $15.3M | 3.64% |
250,385
-3,540
| -1% | -$209K |
|
|
7
Albemarle
ALB
$13.9B
| $14.8M | 3.53% |
87,892
-1,844
| -2% | -$298K |
|
8
Ionis Pharmaceuticals
IONS
$8.6B
| $14.7M | 3.5% |
368,409
-1,889
| -0.5% | -$74K |
|
9
AT&T
T
$159B
| $14M | 3.34% |
644,772
+58,362
| +10% | +$1.33M |
|
10
Bunge Global
BG
$20.4B
| $13.6M | 3.25% |
174,516
+325
| +0.2% | +$27.4K |
|
11
Gilead Sciences
GILD
$162B
| $13.3M | 3.17% |
193,440
-1,360
| -0.7% | -$90.8K |
|
|
12
Cars.com
CARS
$662M
| $12M | 2.87% |
840,070
-21,550
| -3% | -$299K |
|
13
Sysco
SYY
$40.8B
| $11.2M | 2.67% |
144,204
+2,165
| +2% | +$175K |
|
|
14
Pfizer
PFE
$143B
| $10.9M | 2.59% |
277,405
+117,450
| +73% | +$4.57M |
|
|
15
Merck
MRK
$322B
| $10.4M | 2.48% |
133,141
+57,920
| +77% | +$4.31M |
|
|
16
Coca-Cola
KO
$377B
| $9.71M | 2.31% |
178,626
+76,321
| +75% | +$4.15M |
|
|
17
Alphabet (Google) Class A
GOOGL
$4.36T
| $9.22M | 2.2% |
75,560
-2,880
| -4% | -$336K |
|
|
LKCO
18
DELISTED
Luokung Technology Corp Ordinary Shares
LKCO
| $9.22M | 2.2% |
15,191
| – | – |
|
|
19
Wells Fargo
WFC
$261B
| $8.38M | 2% |
185,137
-5,850
| -3% | -$261K |
|
|
PXD
20
DELISTED
Pioneer Natural Resource Co.
PXD
| $8.18M | 1.95% |
50,184
+21
| +0% | +$3.3K |
|
21
Align Technology
ALGN
$12.1B
| $7.09M | 1.69% |
11,609
| – | – |
|
|
22
Campbell Soup
CPB
$6.55B
| $7.02M | 1.67% |
+153,970
| New | +$7.41M |
|
23
Illumina
ILMN
$31B
| $6.68M | 1.59% |
14,510
-62
| -0.4% | -$25K |
|
24
TripAdvisor
TRIP
$1.65B
| $6.21M | 1.48% |
154,226
-2,200
| -1% | -$99.4K |
|
25
Corning
GLW
$119B
| $5.58M | 1.33% |
136,503
-5,450
| -4% | -$238K |
|
Similar funds
AIM
WCM
HP
P8IP
PFPGI
PG
S
LHC
Sicart Associates's Q2 2021 Portfolio in Review
As of Q2 2021, Sicart Associates held 115 positions worth $420M, up 11% from $378M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sicart Associates deployed $32.2M of net new capital in Q2 2021, opening 10 new positions and adding to 24 existing holdings. Its largest new stake was Campbell Soup: 153,970 shares worth $7.02M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Consumer Staples and Materials.
On the sell side, the largest reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, an estimated $2.43M trimmed.
- Sicart Associates's largest Q2 2021 buy was Campbell Soup: 153,970 shares worth $7.02M.
- Sicart Associates added most to Pfizer in Q2 2021, an estimated $4.57M increase.
- Sicart Associates's biggest Q2 2021 reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, cutting an estimated $2.43M.
- Sicart Associates's ten largest holdings make up 44% of its $420M portfolio in Q2 2021.
- Sicart Associates opened 10 new positions and closed 0 in Q2 2021.
- Sicart Associates's portfolio value rose 11% quarter-over-quarter to $420M.
Based on Sicart Associates's 13F filing for Q2 2021, filed 23 Jul 2021.